Physician profile
Effat Rasul
NPI 1699086561
$2,821.66
in general payments reported to CMS, 2019-2025
34 companies · $801 in 2025
The $801 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $165 · 2021: $52.52 · 2022: $374 · 2023: $722 · 2024: $706 · 2025: $801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,230.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $372.29 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $357.14 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $314.52 | 2022-2025 | Mounjaro, Zepbound |
| Abbott Laboratories | $164.52 | 2022-2025 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $135.96 | 2025 | Gemtesa |
| Esperion Therapeutics, INC. | $129.30 | 2022-2025 | Nexletol |
| Boston Scientific Corporation | $120.18 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.60 | 2023-2025 | Jardiance |
| Amgen INC. | $107.89 | 2021-2025 | Repatha, Otezla, Repatha |
| Noven Therapeutics, LLC | $93.00 | 2023-2024 | Xelstrym, Secuado |
| Phathom Pharmaceuticals, INC. | $70.16 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $67.68 | 2019-2023 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $67.05 | 2022-2024 | |
| Supernus Pharmaceuticals, INC. | $66.67 | 2023-2024 | Qelbree, Qelbree |
| Astellas Pharma US INC | $65.63 | 2022-2024 | Veozah, Myrbetriq |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $64.81 | 2022-2024 | |
| Pfizer INC. | $62.36 | 2019-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $61.84 | 2025 | Caplyta |
| Exact Sciences Corporation | $53.38 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Dexcom, INC. | $52.59 | 2024-2025 | Dexcom G6 Transmitter |
| Vifor Pharma, INC. | $37.94 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $24.85 | 2024 | Rexulti |
| Lundbeck LLC | $22.09 | 2024 | Rexulti |
| Antares Pharma, INC. | $21.52 | 2023 | Nocdurna, Tlando, Xyosted |
| Corium, LLC | $20.02 | 2024 | Azstarys |
| Kowa Pharmaceuticals America, INC. | $19.96 | 2022 | |
| Saluda Medical Americas, INC. | $19.33 | 2024 | Evoke |
| Novartis Pharmaceuticals Corporation | $18.58 | 2022 | |
| Shield Therapeutics INC | $17.88 | 2024 | |
| Gilead Sciences, INC. | $17.74 | 2023 | |
| Tris Pharma INC | $16.47 | 2023 | Dyanavel Xr |
| Daiichi Sankyo INC. | $15.44 | 2021 | |
| Ironshore Pharmaceuticals INC. | $15.23 | 2024 | |
| Sanofi-Aventis U.S. LLC | $14.04 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Effat Rasul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.